MicroRNA expression profile associated with 3 response to neoadjuvant chemoradiotherapy in 4 locally advanced rectal cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F12%3A%230000377" target="_blank" >RIV/00209805:_____/12:#0000377 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.ro-journal.com/content/7/1/195" target="_blank" >http://www.ro-journal.com/content/7/1/195</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/1748-717X-7-195" target="_blank" >10.1186/1748-717X-7-195</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MicroRNA expression profile associated with 3 response to neoadjuvant chemoradiotherapy in 4 locally advanced rectal cancer patients

Popis výsledku v původním jazyce

Background: Rectal cancer accounts for approximately one third of all colorectal cancers (CRC), which belong among leading causes of cancer deaths worldwide. Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection. Unfortunately, a significant proportion of tumors do not respond enough to the neoadjuvant treatment and these patients are at risk of relapse. MicroRNAs (miRNAs) are small non-coding RNAs playing significant roles in the pathogenesis of many cancers including rectal cancer. MiRNAs could present the new predictive biomarkers for rectal cancer patients. Methods: We selected 20 patients who underwent neoadjuvant chemoradiotherapy for advanced rectal cancer and whose tumors were classified as most sensitive or resistant to the treatment. These two groups were compared using large-scale miRNA expression profiling. Results: Express

Název v anglickém jazyce

MicroRNA expression profile associated with 3 response to neoadjuvant chemoradiotherapy in 4 locally advanced rectal cancer patients

Popis výsledku anglicky

Background: Rectal cancer accounts for approximately one third of all colorectal cancers (CRC), which belong among leading causes of cancer deaths worldwide. Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection. Unfortunately, a significant proportion of tumors do not respond enough to the neoadjuvant treatment and these patients are at risk of relapse. MicroRNAs (miRNAs) are small non-coding RNAs playing significant roles in the pathogenesis of many cancers including rectal cancer. MiRNAs could present the new predictive biomarkers for rectal cancer patients. Methods: We selected 20 patients who underwent neoadjuvant chemoradiotherapy for advanced rectal cancer and whose tumors were classified as most sensitive or resistant to the treatment. These two groups were compared using large-scale miRNA expression profiling. Results: Express

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13860" target="_blank" >NT13860: Studium signální dráhy EGFR a expresních profilů mikroRNA v predikci odpovědi na cílenou anti-EGFR terapii u pacientů s kolorektálním karcinomem s nemutovanou variantou onkogenu KRAS</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Radiation oncology

ISSN

1748-717X

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

Nov 20

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

000312861600002

EID výsledku v databázi Scopus

—